Lasix (Furosemide) - Summary

LASIX SUMMARY

LASIX is a diuretic which is an anthranilic acid derivative.

LASIX is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. LASIX is particularly useful when an agent with greater diuretic potential is desired. Oral LASIX may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with LASIX alone.

See all Lasix indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Lasix (Furosemide)

The adjunctive effect of nebulized furosemide in COPD exacerbation: a randomized controlled clinical trial. [2013]
department... CONCLUSIONS: Nebulized furosemide benefits patients with COPD exacerbation.

Troponin I release after intravenous treatment with high furosemide doses plus hypertonic saline solution in decompensated heart failure trial (Tra-HSS-Fur). [2012]
with ADHF... CONCLUSIONS: These data demonstrate that intravenous high doses of furosemide do

Furosemide for packed red cell transfusion in preterm infants: a randomized controlled trial. [2011]
electively transfused preterm infants beyond the first week of life... CONCLUSIONS: Routine furosemide in electively transfused preterm infants confers

Furosemide does not improve renal recovery after hemofiltration for acute renal failure in critically ill patients: A double blind randomized controlled trial. [2009.12.26]
OBJECTIVE:: To study the potential beneficial role of furosemide in resolving renal failure after hemofiltration in mechanically ventilated critically ill patients... CONCLUSION:: Furosemide by continuous infusion in the recovery phase of hemofiltration-dependent acute kidney failure did increase urinary volume and sodium excretion but did not lead to a shorter duration of renal failure or more frequent renal recovery.

Randomised, placebo controlled trial of nebulised furosemide for breathlessness in patients with cancer. [2008.10]
CONCLUSIONS: Our findings do not support a beneficial effect from nebulised furosemide in patients with cancer related breathlessness. Listed on the National Research Register (N0170118249) and the UK Clinical Research Network Portfolio Database (1428).

more studies >>

Clinical Trials Related to Lasix (Furosemide)

Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD) [Not yet recruiting]
This study will describe the safety of furosemide in premature infants at risk of bronchopulmonary dysplasia and determine the preliminary effectiveness and pharmacokinetics (PK) of furosemide.

Magnetic Marker Monitoring of Furosemide-containing Gastroretentive Formulation in Healthy Male Subjects (Fasting and Fed Conditions) [Completed]
Furosemide is a diuretic drug, used in the treatment of oedematous states associated with cardiac, renal, and hepatic disorder, and may be effective in patients unresponsive to thiazide diuretics. Furosemide is also used in the treatment of hypertension. Absorption of furosemide from the gastrointestinal tract is fairly rapid; bioavailability is 60-70%, but variable and not predictable, with large intra- and inter-individual variability, and are influenced by dosage form, underlying diseases, and by the presence of food after oral administration. Data from animal model show that furosemide administered into the stomach is more rapidly absorbed than if is administered into the small intestine. To increase the residency of furosemide in the stomach after oral administration, a gastroretentive dosage form (GRDF) of furosemide has been developed. In the current study, the new formulation (30mg furosemide coated tablet) will be tested in healthy male

subjects. Absorption will be characterised by an effective and safe imaging technique -

Magnetic Marker Monitoring (MMM), based on Fe3O4 added to the drug product to generate magnetic signal that can be used for up to 12 h after furosemide administration to localize the medication in the gastrointestinal tract. Fe3O4 is frequently used as colouring pigment in medicinal products. It does not exhibit own pharmacodynamic activity and is considered as an inactive ingredient. In the current study, GRDF formulation of furosemide will be evaluated for: gastric residence as well as pharmacokinetic and pharmacodynamic characteristics under fasting and fed conditions. As part of the study, the subjects will be hospitalized for 1 day during each drug administration. The duration of the stay will depend on the intestinal behaviour of the investigational product.

The Effects of Decreasing the Lasix Dose on the Cardiorenal System [Completed]
The investigators' objective is to define the effects of decreasing the furosemide dose on heart, kidney and humoral function in people with compensated heart failure and kidney dysfunction and also in people with compensated heart failure without kidney dysfunction. Secondly, to define the humoral activation in both groups.

The Use of Furosemide in Patients on Dialysis [Recruiting]
Patients often begin dialysis taking diuretics (stimulate the kidney to excrete salt and water). Once on dialysis, these drugs are often continued. Whether these drugs are still needed, or even effective is often unclear. This study,by evaluating the composition of the patients' urine when off the drug, will predict which patients should benefit from the drug. By comparing their 24 hour volume both off and on the drug, the impact of the drug will be established. The results will allow the prediction of which patients, in the future, should take the drug. The hypothesis is: Among dialysis recipients, evaluation of the random urine sodium concentration will help predict the likelihood of a positive response to Furosemide, as manifested by an increased urine volume and sodium excretion.

Pharmacokinetic Profile and Pharmacodynamic Characteristics of a Furosemide High Dosage Formulation in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis [Completed]
Primary Objective:

- To determine the absolute bioavailability of furosemide 500 mg (Lasix® Special) oral

formulation in patients with chronic renal failure undergoing peritoneal dialysis. Secondary Objectives:

- To determine the pharmacokinetic profiles of furosemide 500 mg (Lasix® Special) oral

formulation and 250 mg IV formulation

- To compare the pharmacodynamic characteristics of furosemide 500 mg (Lasix® Special)

oral formulation and 250 mg IV formulation

more trials >>

PATIENT REVIEWS / RATINGS / COMMENTS

Lasix review by 71 year old female patient
		Rating
Overall rating:
Effectiveness:		Considerably Effective
Side effects:		Severe Side Effects
		Treatment Info
Condition / reason:		Congestive heart failure and edema
Dosage & duration:		20mg at first, later 40 mg, now 20 again taken daily for the period of Been on it for 2 years
Other conditions:		Mitral valve stenosis and prolapse
Other drugs taken:		Toprol XL, Diovan
		Reported Results
Benefits:		When I was first on the 20 mg dosage, there was no apparent benefit. When the dosage was upped to 40 mg, there was dramatic reductio of the edema. Then I had mitral valve surgery and took no Furosemide for a while, but eventually the edema returned and the 20 mg dosage helps some. (see side effects)
Side effects:		I am not aware of any most of the time. However, after my surgery they kept me on 40 mg and I began having dizziness and severe general malaise in the mornings after taking it. (See treatment details.)
Comments:		When I began having the side effects after surgery, the doctor took me off of the Furosemide and the side effect immediately disappeared, and I also had no edema for a few weeks. The doctor then put me back on the 20 mg dosage, which I still take. It seems to help sometimes, but not all of the time.